Payment overview · 2025
General Payments
$1,032.40
38 reported records · 10 companies
Healthcare provider profile · identity verified
Rita Jhaveri, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RICHMOND HILL, NY · NPI 1073554721
Verified facts
What the public records show
CMS Open Payments records show Rita Jhaveri, MD received $1,032.40 in general payments during 2025 across 38 reported records.
AstraZeneca Pharmaceuticals LP accounted for 48.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $497.12 | 48.1% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $179.72 | 17.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $71.55 | 6.9% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $69.54 | 6.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.01 | 5.5% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.67 | 5.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.76 | 4.1% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.79 | 2.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.13 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.11 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,032.40 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $234.07 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $198.33 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $167.88 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $71.55 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $69.54 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $64.72 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $57.01 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $55.67 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.88 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.76 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.76 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $11.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 77 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 142 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
142 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
142 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 575 | 180 |
| Amlodipine Besylate | Amlodipine Besylate | 420 | 123 |
| Metformin Hcl | Metformin Hcl | 399 | 115 |
| Losartan Potassium | Losartan Potassium | 283 | 83 |
| Simvastatin | Simvastatin | 276 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 229 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 194 | 68 |
| Gabapentin | Gabapentin | 183 | 58 |
| Omeprazole | Omeprazole | 183 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 71 |
| Lisinopril | Lisinopril | 167 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 51 |
| Jardiance | Empagliflozin | 142 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 140 | 39 |
| Alendronate Sodium | Alendronate Sodium | 137 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 51 |
| Glimepiride | Glimepiride | 121 | 32 |
| Famotidine | Famotidine | 108 | 42 |
| Januvia | Sitagliptin Phosphate | 107 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 33 |
| Montelukast Sodium | Montelukast Sodium | 99 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 32 |
| Ozempic | Semaglutide | 89 | 18 |
| Atenolol | Atenolol | 84 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 26 |
| Ezetimibe | Ezetimibe | 79 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 30 |
| Farxiga | Dapagliflozin Propanediol | 77 | 22 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 75 | 30 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 75 | 20 |
| Meclizine Hcl | Meclizine Hcl | 75 | 24 |
| Allopurinol | Allopurinol | 74 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 25 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 67 | 24 |
| Metformin Hcl Er | Metformin Hcl | 67 | 19 |
| Naproxen | Naproxen | 65 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 36 |
| Alprazolam | Alprazolam | 62 | 13 |
| Glipizide Er | Glipizide | 61 | 20 |
| Carvedilol | Carvedilol | 59 | 20 |
| Nystatin | Nystatin | 58 | 22 |
| Furosemide | Furosemide | 56 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 16 |
| Donepezil Hcl | Donepezil Hcl | 55 | 21 |
| Valsartan | Valsartan | 54 | 18 |
| Ibuprofen | Ibuprofen | 53 | 14 |
| Meloxicam | Meloxicam | 53 | 24 |
| Eliquis | Apixaban | 50 | 11 |
| Enalapril Maleate | Enalapril Maleate | 48 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | 14 |
| Ramipril | Ramipril | 44 | 14 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 43 | 14 |
| Memantine Hcl | Memantine Hcl | 40 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 14 |
| Single Use Swab | Alcohol Antiseptic Pads | 39 | 15 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Mirtazapine | Mirtazapine | 35 | 13 |
| Sertraline Hcl | Sertraline Hcl | 35 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | 12 |
| Nifedipine Er | Nifedipine | 30 | 11 |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Folic Acid | Folic Acid | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Azithromycin | Azithromycin | 21 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Repaglinide | Repaglinide | 19 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Zolmitriptan | Zolmitriptan | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Prolia | Denosumab | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,032.40 · 38 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, FARXIGA, GVOKE HYPOPEN, JARDIANCE, MOUNJARO, NEXLETOL, Ozempic, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, Veozah, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error